Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

89 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Novel designs and end points for phase II clinical trials.
Adjei AA, Christian M, Ivy P. Adjei AA, et al. Clin Cancer Res. 2009 Mar 15;15(6):1866-72. doi: 10.1158/1078-0432.CCR-08-2035. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276272 Review.
Clinical trials referral resource. Current clinical trials of 17-AG and 17-DMAG.
Ivy PS, Schoenfeldt M. Ivy PS, et al. Oncology (Williston Park). 2004 May;18(5):610, 615, 619-20. Oncology (Williston Park). 2004. PMID: 15209189 No abstract available.
Improving the quality of abstract reporting for phase I cancer trials.
Strevel EL, Chau NG, Pond GR, Murgo AJ, Ivy PS, Siu LL. Strevel EL, et al. Clin Cancer Res. 2008 Mar 15;14(6):1782-7. doi: 10.1158/1078-0432.CCR-07-4886. Clin Cancer Res. 2008. PMID: 18347180

A positive and linear association was observed between average expert rating of the elements and the proportion of P1T abstracts including those elements (Spearman correlation coefficient, rho = 0.60, P < 0.001). ...Year of presentation was found to be significantly ass

A positive and linear association was observed between average expert rating of the elements and the proportion of P1T abstracts including t …
A phase I and pharmacokinetic study of weekly oxaliplatin followed by paclitaxel in patients with solid tumors.
Bekaii-Saab TS, Liu J, Chan KK, Balcerzak SP, Ivy PS, Grever MR, Kraut EH. Bekaii-Saab TS, et al. Clin Cancer Res. 2008 Jun 1;14(11):3434-40. doi: 10.1158/1078-0432.CCR-07-4903. Clin Cancer Res. 2008. PMID: 18519774 Clinical Trial.
The total body clearance values of plasma platinum and ultrafiltrable platinum were higher in this combination compared with corresponding values from our previous study with oxaliplatin only (P < 0.001). ...
The total body clearance values of plasma platinum and ultrafiltrable platinum were higher in this combination compared with corresponding v …
A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.
Heath EI, Gaskins M, Pitot HC, Pili R, Tan W, Marschke R, Liu G, Hillman D, Sarkar F, Sheng S, Erlichman C, Ivy P. Heath EI, et al. Clin Prostate Cancer. 2005 Sep;4(2):138-41. doi: 10.3816/cgc.2005.n.024. Clin Prostate Cancer. 2005. PMID: 16197617 No abstract available.
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
Postel-Vinay S, Collette L, Paoletti X, Rizzo E, Massard C, Olmos D, Fowst C, Levy B, Mancini P, Lacombe D, Ivy P, Seymour L, Le Tourneau C, Siu LL, Kaye SB, Verweij J, Soria JC. Postel-Vinay S, et al. Eur J Cancer. 2014 Aug;50(12):2040-9. doi: 10.1016/j.ejca.2014.04.031. Epub 2014 May 28. Eur J Cancer. 2014. PMID: 24880774
Randomized phase II designs.
Rubinstein L, Crowley J, Ivy P, Leblanc M, Sargent D. Rubinstein L, et al. Clin Cancer Res. 2009 Mar 15;15(6):1883-90. doi: 10.1158/1078-0432.CCR-08-2031. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276275 Free PMC article. Review.
Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial.
Xu R, Shimizu F, Hovinga K, Beal K, Karimi S, Droms L, Peck KK, Gutin P, Iorgulescu JB, Kaley T, DeAngelis L, Pentsova E, Nolan C, Grommes C, Chan T, Bobrow D, Hormigo A, Cross JR, Wu N, Takebe N, Panageas K, Ivy P, Supko JG, Tabar V, Omuro A. Xu R, et al. Among authors: ivy p. Clin Cancer Res. 2016 Oct 1;22(19):4786-4796. doi: 10.1158/1078-0432.CCR-16-0048. Epub 2016 May 6. Clin Cancer Res. 2016. PMID: 27154916 Free PMC article. Clinical Trial.
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.
LoRusso PM, Venkatakrishnan K, Ramanathan RK, Sarantopoulos J, Mulkerin D, Shibata SI, Hamilton A, Dowlati A, Mani S, Rudek MA, Takimoto CH, Neuwirth R, Esseltine DL, Ivy P. LoRusso PM, et al. Clin Cancer Res. 2012 May 15;18(10):2954-63. doi: 10.1158/1078-0432.CCR-11-2873. Epub 2012 Mar 6. Clin Cancer Res. 2012. PMID: 22394984 Free PMC article. Clinical Trial.
89 results
Jump to page
Feedback